Gregory Harriman M.d.

Gregory Harriman, M.D. has an extensive work experience in the healthcare and investment industry. Gregory served as a Partner and Chief Investment Officer at BioAdvance from 2012, where they provided funding to early stage life sciences companies. Gregory also held the position of Venture Partner at BioAdvance from 2012 to 2021. Additionally, they worked as the President of Main Line Ventures starting in 2006.

Dr. Harriman served as a Director at various companies, including Senzo Health from 2022, Opsidio, LLC from 2017, Treventis from 2012, RIBONOVA INC. from 2016 to 2021, Genome Profiling, LLC from 2017 to 2018, Immunome from 2012 to 2017, and Enzium, Inc. from 2015 to 2017. Gregory was also a Member of Robin Hood Ventures from 2010 to 2017.

With their experience in investment and healthcare, Dr. Harriman brings a wealth of knowledge to their current role as Director at Senzo Health and their previous positions in the industry.

Gregory Harriman, M.D. obtained their medical degree, an M.D., from the University of California, San Diego - School of Medicine. Gregory attended this institution from 1977 to 1981, focusing their studies on the field of medicine. Prior to pursuing their medical degree, they completed their undergraduate education at the University of California, Berkeley. Unfortunately, no information is provided regarding the specific degree obtained or field of study during this period.